Optimizing the Use of Hydroxychloroquine in the Management of COVID-19 Given Its Pharmacological Profile

Ali, Ahmed S. and Abdel-Rahman, Mahran S. and Almalikil, Riyadh S. and Mohamed, Abir S. and Alfaifi, Khalid A. and Fadil, Abdelbabgi El. and El-Shitany, Nagla A. and Alkreathy, Huda M. (2020) Optimizing the Use of Hydroxychloroquine in the Management of COVID-19 Given Its Pharmacological Profile. Journal of Pharmaceutical Research International, 32 (8). pp. 29-43. ISSN 2456-9119

[thumbnail of Ali3282020JPRI56916.pdf] Text
Ali3282020JPRI56916.pdf - Published Version

Download (381kB)

Abstract

After the global pandemic of the new coronavirus, its rapid spread and many victims, it is necessary to find an effective vaccine or drugs to overcome it. Most specialists consider that repositioning some medications is the best, fastest and most reliable option for treating patients with the new coronavirus without delay. One of these drugs was an old antimalarial drug, hydroxychloroquine. The current review aimed to explore its potential mechanism, as well as its pharmacokinetics and toxicity, in an attempt to suggest a treatment protocol for its use in treating the COVID-19 virus effectively and safely. This study reviewed the published references on the popular search engines as well as the reference books regarding the pharmacological effects of HCQ. The results of this study suggested the following practical guidelines to optimize HCQ efficacy and safety in the management of COVID-19. HQC should be used as early as possible, i.e., once the viral infection is confirmed or suspected. A loading dose is recommended to be given in 3-4 divided doses to minimize cardiac toxicity. Maintenance daily dose (divided into two doses), should be continued until complete remission. Precautions, drug-interaction, contraindications, variable metabolic pathways in the particular population should be considered. This study suggests more clinical trials regarding the use of HCQ in the management of early identified COVID-19 patients under close medical observation to minimize HCQ cardiac toxicity.

Item Type: Article
Subjects: STM Open Press > Medical Science
Depositing User: Unnamed user with email support@stmopenpress.com
Date Deposited: 04 Apr 2023 06:27
Last Modified: 20 Sep 2024 04:00
URI: http://journal.submissionpages.com/id/eprint/761

Actions (login required)

View Item
View Item